Drugs / ETC-159
Trials 2 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT06513624 | Dec 2024 → Dec 2026 expected | — | National University Hospital, Singapore | Recruiting | No outcome recorded |
| Phase 1 | NCT02521844 | Oct 2015 → Oct 2024 overdue | cancer | EDDC (Experimental Drug Development Centre), A*STAR Research Entities | Active not recruiting | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ETC-159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06513624 ↗ |
| Known as | ETC-1922159 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02521844 ↗ |
| Action | Inhibit | “Wnt pathway inhibition with ETC-159” NCT06513624 ↗ |
| Modality | Small molecule | — CHEMBL3633802 ↗ |
| Route | Oral | “Oral administration” NCT02521844 ↗ |
| Target | PORCN | “ETC-159, as a selective PORCNi” NCT06513624 ↗ |